Program
Rabeprazole
Also written as “rabeprazole”, “rabeprazole sodium” and “E3810”.
Its studies are mostly in Gastroesophageal Reflux · Esophagitis, Peptic · Gastrointestinal Diseases · Stomach Ulcer · Heartburn, led by 13 companies.
Drug pageRabeprazole: every studyMany companies study it; this page follows only the 56 they lead. All 105 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisaiits history only | 210 open or running | phase 3since Sep 12, 2005 | Aug 19, 2005 | none ahead |
| Johnson & Johnsonits history only | 150 open or running | phase 4since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Pfizerits history only | 40 open or running | phase 1since Mar 24, 2014 | Mar 24, 2014 | none ahead |
| GlaxoSmithKlineits history only | 30 open or running | phase 4since May 14, 2015 | Sep 26, 2013 | none ahead |
| Viatris | 30 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Lomond Therapeuticsits history only | 20 open or running | phase 1since May 1, 2024 | May 1, 2024 | none ahead |
| Torrent Pharmaceuticalsits history only | 20 open or running | phase 1since Nov 15, 2013 | Nov 15, 2013 | none ahead |
| Boehringer Ingelheimits history only | 10 open or running | phase 1since May 16, 2022 | May 16, 2022 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 10 open or running | phase 4since May 20, 2013 | May 20, 2013 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Jun 15, 2015 | Jun 15, 2015 | none ahead |
| Neutec Ar-Ge San ve Tic A.Şits history only | 10 open or running | phase 4since Feb 10, 2016 | Feb 10, 2016 | none ahead |
| PriCara, Unit of Ortho-McNeilits history only | 10 open or running | phase 4since Oct 7, 2005 | Oct 7, 2005 | none ahead |
| Yungjin Pharm.its history only | 10 open or running | phase 1since Jan 7, 2021 | Jan 7, 2021 | none ahead |
Also a collaborator on its studies: Ono Pharmaceutical and Pierre Fabre Laboratories.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Viatris only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 30, 2008First studies: 3 phase 1 studies in HealthyFirst studyNCT00649493, NCT00649194, NCT00648349
TargetBeta
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esomeprazolerule | AstraZeneca | phase 4 | 129 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| vonoprazanrule | Takeda | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
All 3 Viatris leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00649493Healthy · United States | 1 | Completed | Jun 2003 | 72 |
| NCT00649194Healthy · United States | 1 | Completed | Aug 2003 | 72 |
| NCT00648349Healthy · United States | 1 | Completed | Jun 2003 | 72 |
How it is read
Names in the registry
- “Rabeprazole”, 15 entries
- “rabeprazole”, 14 entries
- “rabeprazole sodium”, 10 entries
- “E3810”, 8 entries
- “Rabeprazole sodium”, 6 entries
Conditions, from the studies’ own filings
- Gastroesophageal Reflux, 25 studies
- Esophagitis, Peptic, 3 studies
- Gastrointestinal Diseases, 2 studies
- Stomach Ulcer, 2 studies
- Heartburn, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.